Agendia

Podium presentation by Co-Founder and Chief Research Officer Laura van 't Veer introduces an AI-driven approach to MammaPrint Two additional poster presentations from the FLEX Study IRVINE, Calif., and AMSTERDAM, NETHERLANDS, September 25, 2026. Agendia,

Not every woman with early-stage breast cancer needs chemotherapy. Genomic tests like MammaPrint are helping doctors determine who does. When I was diagnosed with Stage IIA breast cancer in late 2017, I thought the hardest decisions had already been made

Agendia's landmark FLEX Study reaches a major enrollment milestone, accelerating real-world insights to advance more personalized breast cancer care IRVINE, Calif, and AMSTERDAM - Sept 24, 2026 - Agendia, Inc., a leader in precision oncology for breast ca

Every woman who receives a diagnosis of breast cancer is unique and requires a personalized treatment plan. An essential part of this plan is to understand the chance that breast cancer may have spread beyond the breast and could come back if not treated

For years, a cancer diagnosis often came down to one test, one gene, one mutation. Today, clinical laboratories are adopting broader approaches-including whole-genome sequencing, functional RNA profiling, liquid biopsy, and multi-omic testing-that provide

IRVINE, Calif.& AMSTERDAM---- Agendia , Inc., a leader in precision oncology for breast cancer, today announced the official ruling by the Swiss Federal Office of Public Health to grant definitive, mandatory health insurance coverage for multigene express

Effective 1 July 2026, Switzerland's FOPH completes its review of multigene expression testing, formally deciding to continue reimbursement indefinitely IRVINE, Calif, and AMSTERDAM - July 14, 2026 - Agendia, Inc., a leader in precision oncology for breas

Hearing the words "you need a biopsy" or "we found something suspicious" during a clinical breast exam, mammogram, or MRI can stop everything in its tracks. Feeling worried or uncertain in that moment is completely natural. One of the first steps toward c

FLEX Study data shows that patients with MammaPrint High Risk 2 tumors have improved 3-year survival with anthracycline-containing regimens, while patients with High Risk 1 tumors show no additional benefit IRVINE, Calif, and AMSTERDAM - June 25, 2026 - A